5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial |
| Type de publication | Journal Article |
| Year of Publication | 2021 |
| Auteurs | Gligorov J., Pivot X., Ataseven B., De Laurentiis M., Llombart A., Jung K.H, Manikhas A., Azim H.A, Alexandrou A., Gupta K., Herraez-Baranda L., Tosti N., Restuccia E. |
| Journal | BREAST |
| Volume | 56 |
| Pagination | S21-S22 |
| Date Published | APR |
| Type of Article | Meeting Abstract |
| ISSN | 0960-9776 |